Gain Therapeutics, Inc. (GANX)
1.79
-0.04
(-2.19%)
USD |
NASDAQ |
Sep 09, 14:06
Gain Therapeutics Shareholders Equity (Quarterly) : 11.29M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 11.29M |
| March 31, 2026 | 14.01M |
| December 31, 2025 | 18.56M |
| September 30, 2025 | 5.909M |
| June 30, 2025 | 3.696M |
| March 31, 2025 | 5.780M |
| December 31, 2024 | 7.340M |
| September 30, 2024 | 8.909M |
| June 30, 2024 | 11.78M |
| March 31, 2024 | 8.642M |
| December 31, 2023 | 12.58M |
| September 30, 2023 | 7.331M |
| June 30, 2023 | 11.09M |
| March 31, 2023 | 15.14M |
| Date | Value |
|---|---|
| December 31, 2022 | 18.88M |
| September 30, 2022 | 22.66M |
| June 30, 2022 | 27.02M |
| March 31, 2022 | 31.83M |
| December 31, 2021 | 34.82M |
| September 30, 2021 | 37.55M |
| June 30, 2021 | 41.39M |
| March 31, 2021 | 44.46M |
| December 31, 2020 | 6.202M |
| September 30, 2020 | 7.828M |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | -0.4499M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Anika Therapeutics, Inc. | 137.28M |
| Savara, Inc. | 143.66M |
| Vericel Corp. | 370.04M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 15.42M |
| Total Liabilities (Quarterly) | 4.130M |
| Debt to Equity Ratio | 0.054 |
| Current Ratio | 4.359 |
| Net Debt Paydown Yield | 0.00% |